{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:27Z","timestamp":1792782867770,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Manfred-Donike Institute for Doping Analysis"},{"name":"Federal Ministry of the Interior of the Federal Republic of Germany","id":[{"id":"https:\/\/ror.org\/00fpwd955","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Anal Bioanal Chem"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00216-018-0934-9","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T23:13:44Z","timestamp":1518563624000},"page":"2275-2281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Analytical challenges in sports drug testing"],"prefix":"10.1007","volume":"410","author":[{"given":"Mario","family":"Thevis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Walpurgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Baume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"934_CR1","unstructured":"WADA. The 2018 Prohibited List. Montreal: Wolrd Anti-Doping Agency; 2017 [cited 26.10.2017]. Available from: \n                    https:\/\/www.wada-ama.org\/sites\/default\/files\/prohibited_list_2018_en.pdf\n                    \n                  ."},{"key":"934_CR2","first-page":"153","volume-title":"Doping in elite sport","author":"B Kidd","year":"2001","unstructured":"Kidd B, Edelman R, Brownell S. Comparative analysis of doping scandals: Canada, Russia, and China. In: Wilson W, Derse E, editors. Doping in elite sport. Chamaign: Human Kinetics; 2001. p. 153\u201388."},{"issue":"12","key":"934_CR3","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/rcm.1495","volume":"18","author":"DH Catlin","year":"2004","unstructured":"Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang Y-C, Hatton CK. Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid Commun Mass Spectrom. 2004;18(12):1245\u20139.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"4","key":"934_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/SPC.0000000000000015","volume":"7","author":"JT Dalton","year":"2013","unstructured":"Dalton JT, Taylor RP, Mohler ML, Steiner MS. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care. 2013;7(4):345\u201351.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"1\u20133","key":"934_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.forsciint.2011.07.014","volume":"213","author":"E Grata","year":"2011","unstructured":"Grata E, Perrenoud L, Saugy M, Baume N. SARM-S4 and metabolites detection in sports drug testing: a case report. Forensic Sci Int. 2011;213(1\u20133):104\u20138.","journal-title":"Forensic Sci Int"},{"key":"934_CR6","doi-asserted-by":"publisher","unstructured":"Thevis M, Volmer DA. Mass spectrometric studies on selective androgen receptor modulators (SARMs) using electron ionization and electrospray ionization\/collision-induced dissociation. Eur J Mass Spectrom. 2017;23. \n                    https:\/\/doi.org\/10.1177\/1469066717731228\n                    \n                  .","DOI":"10.1177\/1469066717731228"},{"issue":"1","key":"934_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/dta.1986","volume":"9","author":"HD Cox","year":"2017","unstructured":"Cox HD, Eichner D. Detection of LGD-4033 and its metabolites in athlete urine samples. Drug Test Anal. 2017;9(1):127\u201334.","journal-title":"Drug Test Anal"},{"key":"934_CR8","unstructured":"McLaren R. The Independent Person 2nd Report: Richard McLaren; 2016 [cited 27.10.2017]. Available from: \n                    https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/mclaren_report_part_ii_2.pdf\n                    \n                  ."},{"issue":"11\u201312","key":"934_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/dta.2051","volume":"8","author":"L Perrenoud","year":"2016","unstructured":"Perrenoud L, Schweizer Grundisch C, Baume N, Saugy M, Nicoli R. Risk of false positive results to SARM S-4 in case of therapeutic use of antineoplastic\/antiandrogen drug containing flutamide: a case study. Drug Test Anal. 2016;8(11\u201312):1109\u201313.","journal-title":"Drug Test Anal"},{"key":"934_CR10","doi-asserted-by":"publisher","unstructured":"Thevis M, Sch\u00e4nzer W. Detection of SARMs in doping control analysis. Mol Cell Endocrinol. 2017;in press; \n                    https:\/\/doi.org\/10.1016\/j.mce.2017.01.040\n                    \n                  .","DOI":"10.1016\/j.mce.2017.01.040"},{"issue":"3","key":"934_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.cell.2008.06.051","volume":"134","author":"VA Narkar","year":"2008","unstructured":"Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008;134(3):405\u201315.","journal-title":"Cell"},{"issue":"10","key":"934_CR12","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1517\/13543784.17.10.1465","volume":"17","author":"AN Billin","year":"2008","unstructured":"Billin AN. PPAR-beta\/delta agonists for type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert Opin Investig Drugs. 2008;17(10):1465\u201371.","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"934_CR13","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00216-009-3283-x","volume":"396","author":"M Thevis","year":"2010","unstructured":"Thevis M, M\u00f6ller I, Thomas A, Beuck S, Rodchenkov G, Bornatsch W, et al. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls. Anal Bioanal Chem. 2010;396(7):2479\u201391.","journal-title":"Anal Bioanal Chem"},{"issue":"8","key":"934_CR14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/13543784.2016.1182981","volume":"25","author":"H Schmid","year":"2016","unstructured":"Schmid H, Jelkmann W. Investigational therapies for renal disease-induced anemia. Expert Opin Investig Drugs. 2016;25(8):901\u201316.","journal-title":"Expert Opin Investig Drugs"},{"key":"934_CR15","doi-asserted-by":"publisher","unstructured":"Eichner D, Van Wagoner RM, Brenner M, Chou J, Leigh S, Wright LR, et al. Implementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls. Drug Test Anal. 2017; \n                    https:\/\/doi.org\/10.1002\/dta.2202\n                    \n                  .","DOI":"10.1002\/dta.2202"},{"key":"934_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/dta.2011","volume":"9","author":"J Dib","year":"2017","unstructured":"Dib J, Mongongu C, Buisson C, Molina A, Sch\u00e4nzer W, Thuss U, et al. Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls. Drug Test Anal. 2017;9:61\u20137.","journal-title":"Drug Test Anal"},{"key":"934_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jpba.2016.01.029","volume":"121","author":"C Buisson","year":"2016","unstructured":"Buisson C, Marchand A, Bailloux I, Lahaussois A, Martin L, Molina A. Detection by LC-MS\/MS of HIF stabilizer FG-4592 used as a new doping agent: investigation on a positive case. J Pharm Biomed Anal. 2016;121:181\u20137.","journal-title":"J Pharm Biomed Anal"},{"key":"934_CR18","unstructured":"CyclingNews. Kvasina positive for EPO stimulator at Fleche du Sud: CyclingNews; 2017 [cited 05\u201307-2017]. Available from: \n                    http:\/\/www.cyclingnews.com\/news\/kvasina-positive-for-epo-stimulator-at-fleche-du-sud\/\n                    \n                  ."},{"issue":"11\u201312","key":"934_CR19","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/dta.2093","volume":"8","author":"K Walpurgis","year":"2016","unstructured":"Walpurgis K, Thomas A, Vogel M, Reichel C, Geyer H, Sch\u00e4nzer W, et al. Testing for the erythropoiesis-stimulating agent Sotatercept\/ACE-011 (ActRIIA-Fc) in serum by means of western blotting and LC-HRMS. Drug Test Anal. 2016;8(11\u201312):1152\u201361.","journal-title":"Drug Test Anal"},{"key":"934_CR20","doi-asserted-by":"publisher","unstructured":"Reichel C, Gmeiner G, Thevis M. Antibody-based strategies for the detection of luspatercept (ACE-536) in human serum. Drug Test Anal. 2017; \n                    https:\/\/doi.org\/10.1002\/dta.2302\n                    \n                  .","DOI":"10.1002\/dta.2302"},{"key":"934_CR21","unstructured":"WADA. World Anti-Doping Code. Montreal: World Anti-Doping Agency; 2015 [cited 12\u201304-2016]. Available from: https:\/\/wada-main-prod.s3.\n                    amazonaws.com\/resources\/files\/wada-2015-world-anti-doping-code.pdf\n                    \n                  ."},{"key":"934_CR22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/dta.1471","volume":"5","author":"M Thevis","year":"2013","unstructured":"Thevis M, Geyer L, Geyer H, Guddat S, Dvorak J, Butch A, et al. Adverse analytical findings with clenbuterol among U-17 soccer players attributed to food contamination issues. Drug Test Anal. 2013;5:372\u20136.","journal-title":"Drug Test Anal"},{"issue":"11\u201312","key":"934_CR23","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/dta.1746","volume":"6","author":"A Krumbholz","year":"2014","unstructured":"Krumbholz A, Anielski P, Gfrerer L, Graw M, Geyer H, Schanzer W, et al. Statistical significance of hair analysis of clenbuterol to discriminate therapeutic use from contamination. Drug Test Anal. 2014;6(11\u201312):1108\u201316.","journal-title":"Drug Test Anal"},{"issue":"4","key":"934_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/19440049.2016.1242169","volume":"34","author":"MK Parr","year":"2017","unstructured":"Parr MK, Blokland MH, Liebetrau F, Schmidt AH, Meijer T, Stanic M, et al. Distinction of clenbuterol intake from drug or contaminated food of animal origin in a controlled administration trial\u2014the potential of enantiomeric separation for doping control analysis. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2017;34(4):525\u201335.","journal-title":"Food Addit Contam Part A Chem Anal Control Expo Risk Assess"},{"key":"934_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.forsciint.2016.08.029","volume":"267","author":"H-J Helmlin","year":"2016","unstructured":"Helmlin H-J, M\u00fcrner A, Steiner S, Kamber M, Weber C, Geyer H, et al. Detection of the diuretic hydrochlorothiazide in a doping control urine sample as the result of a non-steroidal anti-inflammatory drug (NSAID) tablet contamination. Forensic Sci Int. 2016;267:166\u201372.","journal-title":"Forensic Sci Int"},{"key":"934_CR26","unstructured":"USADA. U.S. Volleyball Athlete Alexandra Klineman Accepts Finding of No Fault for Anti-Doping Rule Violation Colorado Springs: U.S. Anti-Doping Agency; 2017 [cited 17\u201311-2017]. Available from: \n                    https:\/\/www.usada.org\/alexandra-klineman-accepts-finding-no-fault\/\n                    \n                  ."},{"key":"934_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jpba.2015.07.017","volume":"115","author":"M Thevis","year":"2015","unstructured":"Thevis M, Geyer H, Thomas A, Tretzel L, Bailloux I, Buisson C, et al. Formation of the diuretic chlorazanil from the antimalarial drug proguanil\u2014implications for sports drug testing. J Pharm Biomed Anal. 2015;115:208\u201313.","journal-title":"J Pharm Biomed Anal"},{"key":"934_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jpba.2011.09.002","volume":"57","author":"M Thevis","year":"2012","unstructured":"Thevis M, Geyer H, Sigmund G, Sch\u00e4nzer W. Sports drug testing: analytical aspects of selected cases of suspected, purported, and proven urine manipulation. J Pharm Biomed Anal. 2012;57:26\u201332.","journal-title":"J Pharm Biomed Anal"},{"key":"934_CR29","volume-title":"The cologne protocol to follow up high testosterone\/epitestosterone ratios. Recent advances in doping analysis","year":"1997","unstructured":"Geyer H, Mareck U, Sch\u00e4nzer W, Donike M, editors. The cologne protocol to follow up high testosterone\/epitestosterone ratios. Recent advances in doping analysis. Cologne: Sport und Buch Strauss; 1997."},{"key":"934_CR30","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s00216-006-1112-z","volume":"388","author":"M Thevis","year":"2007","unstructured":"Thevis M, Geyer H, Mareck U, Sigmund G, Henke J, Henke L, et al. Detection of manipulation in doping control urine sample collection: a multidisciplinary approach to determine identical urine samples. Anal Bioanal Chem. 2007;388:1539\u201343.","journal-title":"Anal Bioanal Chem"}],"container-title":["Analytical and Bioanalytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00216-018-0934-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-018-0934-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-018-0934-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T20:10:42Z","timestamp":1550088642000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00216-018-0934-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,14]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1007\/s00216-018-0934-9","relation":{},"ISSN":["1618-2642","1618-2650"],"issn-type":[{"value":"1618-2642","type":"print"},{"value":"1618-2650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,14]]},"assertion":[{"value":"12 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}